New combo therapy trial for Tough-to-Treat skin cancers
NCT ID NCT03901573
Summary
This study tested whether adding an experimental drug called NT-I7 to an existing immunotherapy (atezolizumab) could help control advanced skin cancers. It focused on patients whose cancers had not responded to or had returned after similar treatments. The main goals were to find a safe dose and see if the combination could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44106, United States
-
Dana Farber
Boston, Massachusetts, 02215, United States
-
MGH
Boston, Massachusetts, 02215, United States
-
Mt Sinai
New York, New York, 10029, United States
-
Northwestern University
Chicago, Illinois, 60208, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.